Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy
Clinical trial NCT04318223 · UNKNOWN
Trial details
- NCT number
- NCT04318223
- Sponsor
- Consorzio Oncotech
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-16
- Primary completion
- 2023-07-31
- Enrollment
- 168
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.